Predicting 5-Aminosalicylate Nephrotoxicity in Patients with IBD (New Trial)
This is the first of a series of genetic studies, lead by the UK IBD Genetics consortium, investigating rare side effects to drugs used in patients with IBD. Our aim is to recruit 200 UK patients over the next 2 years. We anticipate that each hospital might be looking after 2-3 patients who meet the inclusion criteria. Participation involves a blood test for DNA extraction, and completion of a case report form, patient questionnaire and consent form.
Nephrotoxicity is defined by a series of major and minor criteria which allow us to rank how certain we are that the 5-ASA is responsible. Any patient that meets the major criteria might be eligible: Current age > 18 years; normal Creatinine or eGFR at baseline; ≥50% rise in serum creatinine (with corresponding fall in eGFR, anytime after introduction of 5-ASA; expert renal opinion implicates 5-ASA
If would like to get involved, either as a research site or patient identification (PIC) site then please contact:
Tel: 07900 161244